Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study

Maureen M. Jonas, Robert H. Squires, Susan M. Rhee, Chih‐Wei Lin, Kazuhiko Bessho, Cornelia Feiterna‐Sperling, Loreto Hierro, Deirdre Kelly, Simon C. Ling, Tatiana Strokova, Antonio Valle‐Segarra, Sandra Lovell, Wei Liu, Teresa I. Ng, Ariel Porcalla, Yuri Sanchez Gonzalez, Margaret Burroughs, Etienne Sokal – 29 June 2019 – The pangenotypic regimen of glecaprevir and pibrentasvir (G/P) is approved to treat adults with chronic hepatitis C virus (HCV) infection and has yielded high cure rates in adults in clinical trials. Approved treatment options for pediatrics may include ribavirin.

Hepatology Highlights

Jaspreet S. Suri, Ghideon Ezaz, Daryl T.Y. Lau, Tasha B. Kulai, Harmeet Malhi, Zaid H. Tafesh, Brett Fortune, Russell Rosenblatt, Robert S. Brown, Joseph F. Pisa, Nicholas Russo, Petra Hirsova, Robert E. Schwartz, Sayed Obaidullah Aseem, Nidhi Jalan‐Sakrikar, Vikas Gupta – 28 June 2019

Hepatology Highlights

Omar Y. Mousa, Harmeet Malhi, Nicholas Russo, Arun Jesudian, Joseph F. Pisa, Tasha B. Kulai, Jessica L. Maiers, Enis Kostallari, Nidhi Jalan‐Sakrikar, Zaid H. Tafesh, Brett E. Fortune, Lauren Yang, Daryl T.Y. Lau, Kavitha Nair, Joel Wedd – 28 June 2019

Subscribe to